Telix gets FDA Fast Track for BiPASS pre-biopsy prostate imaging program
The designation applies to Telix's 68Ga-PSMA-PET imaging combined with MRI for detecting prostate cancer before biopsy, announced September 30, 2026.
SEC filing
3 stories
The designation applies to Telix's 68Ga-PSMA-PET imaging combined with MRI for detecting prostate cancer before biopsy, announced September 30, 2026.
SEC filing
Telix will pay ITM shareholders $1.65 billion upfront and up to $700 million more tied to regulatory and sales milestones for cancer drug candidate ITM-11.
SEC filing
The agency cleared the first FET-PET imaging drug for brain cancer, allowing use in adults and pediatric patients as young as 1 month old.
SEC filing